Search

Inherited progressive sight loss is caused by a range of rare genetic conditions. We specialise in those which affect the retina.

An American living with Leber congenital amaurosis 10 (LCA10) has become the first clinical trial participant in the world to receive a CRISPR gene editing treatment in vivo (inside the body).

• News
• Leber congenital amaurosis (LCA)

There are many ongoing clinical and laboratory studies around the world, exploring innovative approaches to treating inherited sight loss.

• News

Inherited retinal dystrophies (IRDs) are the leading cause of blindness in working-age people in the UK, and children as young as eighteen-months are regularly diagnosed.

Luxturna, a gene therapy, is only for the treatment of Leber congenital amaurosis type 2 (LCA2) and severe early-onset RP caused by mutations in a specific gene called RPE65.

• FAQ
• Written

Did you join either of our Conferences this year? You can read about them inside this edition of Look Forward. We’ve had some fantastic feedback from our delegates so if you weren’t able to attend, you can watch or listen to the recordings from the day on our website.

• Look Forward
• Audio
• Written

Retina UK is delighted to announce that it has awarded three new research grants worth more than £870,000.

• News
• Leber congenital amaurosis (LCA)
• Retinitis pigmentosa

Biotechnology company ProQR has announced that its clinical trials of sepofarsen for Leber congenital amaurosis type 10 and ultevursen for USH2A-mediated retinitis pigmentosa will be wound down with immediate effect.

• News

Retina UK aims not only to progress research along established threads, but to stimulate new thinking, encourage innovative approaches and nurture original ideas.

The following projects were being funded by Retina UK and have recently come to an end.